Prostatype Genomics provides update on the Medicare process regarding Prostatype®
Prostatype Genomics provides update on the Medicare process regarding Prostatype®
Prostatype Genomics AB today provides an update regarding the ongoing process for Medicare reimbursement for Prostatype® in the US. The process is continuing, and the dialogue is now focused on a limited number of remaining issues. At this stage, the Company cannot specify when a final decision might be expected.
In the most recent interaction with Medicare, Prostatype Genomics received a few additional questions to address, and the company is currently compiling the requested information. The dialogue has gradually become more focused and streamlined. At the same time, there is no set deadline for the conclusion of the process. Prostatype Genomics therefore does not wish to speculate on the timing of a final decision, as this is not within the Company’s control.
The requirements for obtaining reimbursement for prognostic biomarkers in prostate cancer are extensive. Prostatype Genomics views the high standards for scientific and clinical documentation as both reasonable and necessary in a field where the results of prognostic tests can form a crucial part of the basis for treatment decisions.
Fredrik Rickman, CEO of Prostatype Genomics, comments:
"We understand that our shareholders and other stakeholders are awaiting a final decision, and we ourselves would naturally have preferred for the process to have concluded already. However, it is important to distinguish between a process that takes time and one that is not moving forward. The process is continuing; the remaining issues to be discussed are limited in number, and the dialogue is proceeding in a constructive spirit."
A positive decision regarding Medicare reimbursement will represent a significant commercial milestone for Prostatype Genomics and the company’s continued establishment in the US market. The company will inform the market when there is further relevant information regarding the process.
For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: [email protected]
Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: [email protected]
About Prostatype Genomics
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.